Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

iBio Inc., GE Healthcare form global alliance

By Drug Discovery Trends Editor | July 26, 2012

iBio Inc. and
GE Healthcare announced a new global alliance to commercialize plant-based
technologies for the manufacture of biopharmaceuticals and vaccines. The
alliance builds on the existing development and marketing agreement between the
two companies announced in 2010 and combines iBio’s plant-based vaccine
manufacturing platform, iBioLaunch, with GE Healthcare’s capabilities in
start-to-finish technologies for biopharmaceutical manufacturing. iBio’s
R&D collaborator, Fraunhofer USA Center for Molecular Biotechnology (CMB)
will continue to play a key role in advancing the iBioLaunch platform. Financial
terms were not disclosed.

The iBioLaunch platform is a proprietary gene expression
technology that induces plants to rapidly produce high levels of proteins such as
vaccines, in a process which can be easily and reliably scaled-up in low cost,
controlled-growth facilities. GE Healthcare develops and produces
start-to-finish technologies and tools used for the manufacture of
biopharmaceuticals, vaccines, and other protein-based therapeutics. GE
Healthcare’s global team of bioengineers and bioprocessing scientists are
working with researchers from iBio and CMB to develop a single, flexible
facility which could significantly reduce the capital and operating costs of
biotherapeutic and vaccine manufacture compared with traditional animal cell
and microbial based methods. The iBioLaunch platform also has the potential to
manufacture proteins which cannot be commercially produced in any other system.

Worldwide
demand for biopharmaceuticals and vaccines is increasing dramatically, driven
by ageing populations and the global effort to reduce the incidence of vaccine
preventable diseases. In work funded by the Bill & Melinda Gates
Foundation, iBio’s plant-based technology has been used to produce an avian
influenza vaccine candidate that recently completed a successful Phase I
clinical trial. The iBioLaunch platform was also used to produce a candidate
vaccine against H1N1 influenza, for which a human Phase I trial was
successfully completed in March, 2012.  The alliance between the two
companies aligns with GE’s healthymagination initiative, which focuses on
reducing cost, increasing access and improving quality in health care.

GE Healthcare


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50